Profile data is unavailable for this security.
About the company
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
- Revenue in USD (TTM)1.06m
- Net income in USD-29.36m
- Incorporated2005
- Employees39.00
- LocationVistagen Therapeutics Inc343 ALLERTON AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 577-3600
- Websitehttps://www.vistagen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics Inc | 68.00k | -52.32m | 97.09m | 23.00 | -- | -- | -- | 1,427.79 | -2.37 | -2.37 | 0.0028 | -0.2872 | 0.0076 | -- | -- | 2,956.52 | -585.51 | -142.43 | -- | -342.79 | -- | -- | -76,938.23 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.50m | 99.15m | 68.00 | -- | 0.8587 | -- | -- | -1.86 | -1.86 | 0.00 | 1.75 | 0.00 | -- | -- | 0.00 | -66.79 | -- | -72.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -485.01m | 99.37m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 99.77m | 91.00 | -- | 0.7024 | -- | 3.21 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.92m | 104.36m | 10.00 | -- | 0.5492 | -- | 52.18 | -1.23 | -1.23 | 0.0862 | 5.95 | 0.018 | -- | -- | 200,000.00 | -25.18 | -- | -26.34 | -- | -- | -- | -1,395.90 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 106.14m | 126.00 | -- | 0.8112 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Omega Therapeutics Inc | 4.94m | -92.28m | 106.45m | 93.00 | -- | 2.57 | -- | 21.55 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.06m | -29.36m | 106.60m | 39.00 | -- | 0.9317 | -- | 100.19 | -2.12 | -2.12 | 0.055 | 4.23 | 0.0147 | -- | -- | 27,282.05 | -40.57 | -62.84 | -43.48 | -68.03 | -- | -- | -2,759.59 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Oramed Pharmaceuticals, Inc. | 674.00k | 10.46m | 106.85m | 15.00 | 10.57 | 0.6395 | 10.23 | 158.54 | 0.2488 | 0.2488 | 0.0165 | 4.11 | 0.0037 | -- | -- | 44,933.33 | 5.63 | -- | 6.27 | -- | -- | -- | 1,518.25 | -- | -- | -- | 0.162 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 4.70m | -79.58m | 108.46m | 66.00 | -- | -- | -- | 23.08 | -2.20 | -2.20 | 0.1302 | -1.56 | 0.041 | -- | 3.16 | 71,196.97 | -69.46 | -59.78 | -235.17 | -72.70 | -- | -- | -1,693.47 | -1,113.72 | -- | -1.11 | 1.75 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Cardiff Oncology Inc | 610.00k | -40.25m | 108.68m | 31.00 | -- | 1.78 | -- | 178.17 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
| Coya Therapeutics Inc | 6.13m | -10.30m | 109.29m | 8.00 | -- | 3.24 | -- | 17.83 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 112.20m | 120.00 | 7.28 | -- | 6.04 | 0.9415 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 113.91m | 28.00 | -- | 1.06 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 115.32m | 325.00 | -- | -- | -- | 0.821 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Vistagen Therapeutics Inc's reporting currency: US Dollar USD
47.54%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Mar 2024 | 2.00m | 7.40% |
| Great Point Partners LLCas of 31 Mar 2024 | 1.86m | 6.88% |
| StemPoint Capital LPas of 31 Mar 2024 | 1.85m | 6.84% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.78m | 6.60% |
| Commodore Capital LPas of 31 Mar 2024 | 1.58m | 5.83% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 1.52m | 5.62% |
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 808.55k | 2.99% |
| Citadel Advisors LLCas of 31 Mar 2024 | 743.50k | 2.75% |
| Armistice Capital LLCas of 31 Mar 2024 | 364.00k | 1.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 348.44k | 1.29% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
